REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT04400695
- Locations
- 🇨🇳
Oncology Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT04329429
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳First Hospital of Jilin University, Chang chun, Jilin, China
🇨🇳Peking University Cancer Hospital & Institute, Beijing, Beijing, China
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT04311034
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
- Conditions
- Systemic Myasthenia Gravis
- Interventions
- Biological: RC18 160mgBiological: RC18 240 mg
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT04302103
- Locations
- 🇨🇳
Beijing Tiantan Hospital,Capital Medical University, Beijing, Beijing, China
A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy
- Conditions
- Primary IgA Nephropathy
- Interventions
- Biological: placeboBiological: RC18 160mgBiological: RC18 240mg
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT04291781
- Locations
- 🇨🇳
Peking University First Hospital., Beijing, Beijing, China
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
- Conditions
- Wet Age-Related Macular Degeneration
- Interventions
- Biological: intravitreal injection of RC28-E 0.5mgBiological: intravitreal injection of RC28-E 1.0mgBiological: intravitreal injection of RC28-E2.0mg
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT04270669
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects
- Conditions
- Healthy
- Interventions
- Biological: Tai Ai(RC18) 80mgBiological: RC18 240mgBiological: Tai Ai(RC18) 160mg
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04235933
- Locations
- 🇨🇳
Remegen，ltd., Yantai, Shandong, China
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04190823
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
A Phase I /IIa Study of RC88-ADC in Subjects with Advanced Malignant Solid Tumors
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT04175847
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Drum Tower Hospital, Nanjing, Jiangsu, China
Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Placebo plus standard therapyBiological: RC18 160 mg plus standard therapy
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 335
- Registration Number
- NCT04082416
- Locations
- 🇨🇳
Remegen，ltd., Yantai, Shandong, China